Table 1.
Clinicopathological characteristics between false-negative and true-negative group for sentinel lymph node biopsy
| Characteristic | False-negative (n=179) | True-negative (n=1,707) | p-value |
|---|---|---|---|
| Age (yr) | |||
| ≤ 50 | 97 (54.2) | 996 (58.3) | 0.288 |
| > 50 | 82 (45.8) | 712 (41.7) | |
| Mean (range) | 50.0 (27-74) | 50.0 (22-87) | |
| Type of breast surgery | |||
| Total mastectomy | 109 (60.6) | 922 (54.0) | 0.065 |
| Breast conserving surgery | 70 (39.4) | 785 (46.0) | |
| T stage | |||
| T1 | 101 (56.4) | 1,173 (68.7) | 0.007 |
| T2 | 76 (42.5) | 518 (30.3) | |
| ≥ T3 | 2 (1.1) | 16 (0.9) | |
| Tumor size, mean (range, cm) | 2.10 (0.4-6.3) | 1.80 (0.1-8.5) | |
| Histology type | |||
| Infiltrating ductal | 162 (90.5) | 1,427 (83.5) | 0.053 |
| Lobular | 4 (2.2) | 71 (4.2) | |
| Other | 13 (7.3) | 210 (12.3) | |
| Modifier Bloom-Richardson score | |||
| I | 41 (24.6) | 362 (23.5) | 0.679 |
| II | 84 (50.3) | 739 (48.0) | |
| III | 42 (25.1) | 438 (28.5) | |
| Missing | 12 | 169 | |
| Estrogen receptor | |||
| Positive | 119 (67.2) | 1,132 (66.6) | 0.863 |
| Negative | 58 (32.8) | 568 (33.4) | |
| Missing | 2 | 7 | |
| Progesterone receptor | |||
| Positive | 111 (63.1) | 988 (58.6) | 0.260 |
| Negative | 65 (36.9) | 699 (41.4) | |
| Missing | 3 | 21 | |
| HER2 | |||
| Positivea) | 41 (27) | 258 (17.8) | 0.006 |
| Negative | 111 (73) | 1,195 (82.2) | |
| Missing | 27 | 255 | |
| Subgroup | |||
| HR(+)HER2(‒) | 84 (53.8) | 862 (57) | 0.018 |
| HR(+)HER2(+) | 25 (16) | 138 (9.1) | |
| HR(‒)HER2(+) | 16 (10.3) | 120 (7.9) | |
| HR(‒)HER2(‒) | 31 (19.9) | 392 (25.9) | |
| Lymphovascular invasion | |||
| Positive | 20 (18.5) | 73 (8.3) | 0.001 |
| Negative | 88 (81.5) | 806 (91.7) | |
| Missing | 71 | 829 | |
| No. of dissected sentinel nodes | |||
| 1 | 78 (43.6) | 520 (30.4) | 0.002 |
| 2 | 48 (26.8) | 446 (26.1) | |
| 3 | 24 (13.4) | 280 (16.4) | |
| 4 | 12 (6.7) | 216 (12.6) | |
| ≥ 5 | 17 (9.5) | 246 (14.4) | |
| No. of metastatic lymph nodes | |||
| 1 | 123 (68.7) | - | - |
| 2 | 26 (14.5) | - | |
| 3 | 6 (3.4) | - | |
| ≥ 4 | 24 (13.4) | - | |
| Tumor location | |||
| Upper outer | 113 (63.1) | 829 (49.0) | < 0.001 |
| Upper inner | 21 (11.7) | 367 (21.7) | |
| Lower outer | 23 (12.8) | 151 (8.9) | |
| Lower inner | 6 (3.4) | 88 (5.2) | |
| Central | 16 (8.9) | 257 (15.2) | |
| Imaging assessment | |||
| Positiveb) | 77 (45.8) | 372 (22.8) | < 0.001 |
| Negativec) | 91 (54.2) | 1,258 (77.2) | |
| Adjuvant treatment | |||
| Chemotherapy | 169 (96.6) | 1,043 (62.1) | < 0.001 |
| Anti-hormone therapy | 121 (69.5) | 1,171 (69.2) | 0.928 |
| Radiation therapy | 97 (55.1) | 794 (46.5) | 0.033 |
Values are presented as number (%). HR, hormone receptor; HER2, human epidermal growth factor receptor 2.
a)
HER-2 positive was defined by three positive on immunohistochemistry or amplification on fluorescence in situ hybridization,
b)
Image positive was defined as suspicious axillary lymph nodes on one or more imaging studies,
c)
Image negative was defined as non-suspicious axillary lymph nodes on all imaging studies.